OnabotulinumtoxinA for chronic migraine: A critical appraisal

Citations of this article
Mendeley users who have this article in their library.


Chronic migraine (CM) is a severe disabling condition with a few available evidence-based management options. OnabotulinumtoxinA (onaBoNTA) is approved for use in a number of disorders. Its benefits and potential use in migraine were observed incidentally while treating patients cosmetically for wrinkles. The mechanism of action of onaBoNTA in CM is not fully understood, but there is evidence that this involves axonal transport via sensory fibers. The Phase III REsearch Evaluating Migraine Prophylaxis Therapy trials have established the efficacy as well as the long-term safety and tolerability of onaBoNTA in CM. This review will discuss the evidence behind its use in this setting.




Gooriah, R., & Ahmed, F. (2015, June 29). OnabotulinumtoxinA for chronic migraine: A critical appraisal. Therapeutics and Clinical Risk Management. Dove Medical Press Ltd. https://doi.org/10.2147/TCRM.S76964

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free